Organization
Philogen
20 clinical trials
Clinical trial
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Lomustine in Patients With Glioblastoma at First ProgressionStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Dose Optimization Study for L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or RecurrenceStatus: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Phase III Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Study to Evaluate the Safety and Efficacy of Different Administration Sequences of L19TNF in Combination With Lomustine in Patients With Glioblastoma at First ProgressionStatus: Withdrawn, Estimated PCD: 2024-12-31
Clinical trial
A Dose Finding Study of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Combination With Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Pivotal Phase III, Open-label, Randomized, Controlled Multi-center Study of the Efficacy of L19IL2/L19TNF Neoadjuvant Intratumoral Treatment Followed by Surgery Versus Surgery Alone in Clinical Stage III B/C Melanoma PatientsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination With Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients With Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and With Presence of Injectable MetastasesStatus: Active (not recruiting), Estimated PCD: 2028-07-01
Clinical trial
A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients With Solid TumorsStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase I Study to Evaluate Safety and Early Signs of Efficacy of the Human Monoclonal Antibody-cytokine Fusion Protein IL12-L19L19.Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue SarcomaStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate Safety and Clinical Efficacy of Two Different Doses of F8IL10 (Dekavil) Administered Subcutaneously to Patients With Active Rheumatoid Arthritis Receiving Methotrexate.Status: Terminated, Estimated PCD: 2019-04-01
Clinical trial
A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status: Terminated, Estimated PCD: 2023-09-01
Clinical trial
A Phase II Study of Intratumoral Administration of L19IL2/L19TNF in Non-melanoma Skin Cancer Patients With Presence of Injectable LesionsStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Dose-finding Phase I Study of F8IL10 Intra-articular Treatment in Rheumatoid ArthritisStatus: Not yet recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study of L19IL2/L19TNF in Patients With Skin Cancers Amenable to Intralesional TreatmentStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell TransplantationStatus: Terminated, Estimated PCD: 2023-09-29
Clinical trial
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First RelapseStatus: Completed, Estimated PCD: 2023-06-27
Clinical trial
An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma PatientsStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Study to Evaluate the Safety and Efficacy of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF Plus Standard Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed GlioblastomaStatus: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic LeiomyosarcomaStatus: Recruiting, Estimated PCD: 2024-12-01